Table 4

Exploratory variables

HITStandard careTreatment effectP
n=29n=37
Baseline12 monthsBaseline12 monthsChange (95% CI)
Clinical features
 Weight, kg75±1381±16*78±1581±17*2.9 (0.02 to 5.86)0.05
 Body mass index, kg/m224.4±3.326.4±4.0*25.3±3.926.3±4.3*1.0 (0.1 to 2.0)0.04
 Systolic BP, mm Hg131±10139±11*133±13135±156.7 (0.5 to 12.9)0.03
 Diastolic BP, mm Hg79±586±6*81±883±115.1 (1.0 to 9.1)0.01
Biochemistry
 CRP, mg/L2.7 (1.0 to 4.2)2.0 (0.6 to 5.5)2.3 (0.9 to 6.7)2.0 (0.6 to 3.8)8.2 (0.6 to 15.8)0.03
 HbA1c, %5.5 (5.1 to 6.4)5.8 (5.2 to 6.8)5.4 (5.0 to 6.0)5.5 (5.2 to 5.8)0.3 (–0.1 to 0.6)0.12
 Total cholesterol, mmol/L5.0 (4.6 to 5.8)5.1 (4.5 to 5.5)4.8 (4.3 to 5.7)4.5 (3.7 to 6.1)–0.1 (–0.8 to 0.6)0.78
 LDL cholesterol, mmol/L2.8 (2.3 to 3.5)2.9 (2.4 to 3.2)2.7 (2.1 to 3.1)2.4 (2.0 to 3.3)–0.2 (–0.6 to 0.3)0.43
 HS-troponin T, ng/L27 (19 to 66)11 (7 to 20)*33 (20 to 56)13 (8 to 27)*–1.0 (–17.4 to 15.5)0.91
 NT-proBNP, pmol/L100 (64 to 217)42 (14 to 61)*108 (74 to 173)28 (19 to 58)*–43 (–102 to 15)0.15
 Creatinine, µmol/L117±3599±21*119±29104±28*–2.7 (–14.5 to 9.1)0.65
Rejection score0.38
 019 (66)18 (62)22 (59)17 (46)
 16 (21)5 (17)7 (19)9 (24)
 21 (3)2 (7)4 (11)6 (16)
 32 (7)2 (7)1 (3)0
 401 (3)1 (3)1 (3)
 5002 (5)2 (5)
 61 (3)002 (5)
 70000
 801 (3)00
Peak oxygens consumption, L/min1.5±0.42.0±0.6*1.6±0.42.0±0.6*0.2 (–0.01 to 0.33)0.06
Right heart catheterisation
 RAP, mm Hg5±34±35±34±3*0.7 (–1.2 to 2.6)0.46
 PCWP, mm Hg13±610±5*11±510±5–1.5 (–4.0 to 1.1)0.27
 CO, L/min7.0±1.77.0±1.96.6±1.76.9±1.5–0.2 (–1.0 to 0.6)0.59
 CI, L/min/m23.9±1.13.7±0.83.4±0.84.1±3.5–1.0 (–2.3 to 0.5)0.20
  • Data are n (%), median (IQR), or mean±SD values. P values are from mixed-effects multilevel regression and are for between-groups comparisons.

  • *P<0.05 within group.

  • CAV, cardiac allograft vasculopathy; CRP, C reactive protein; HbA1c, glycated haemoglobin; HIT, high-intensity interval training; HS, high sensitivity; LDL, low-density lipoprotein; NT-proBNP, N-terminal pro-brain natriuretic peptide.